

Financial news for OCRX dated on 2017-12-11: Mallinckrodt Reports Closing Of Ocera Therapeutics Deal

Financial news for OCRX dated on 2017-12-11: Ocera Therapeutics Shares Halted With Code T12 Added Info Requested By Nasdaq

Financial news for OCRX dated on 2017-11-03: H.C. Wainwright Downgrades Ocera Therapeutics to Neutral

Financial news for OCRX dated on 2017-11-02: Ocera Therapeutics Shares Up 66% Following \$1.52/Share Offer From Mallinckrodt; Stock Currently Trading 11% Above Offer Price

Financial news for OCRX dated on 2017-11-02: Ocerta Therapeutics to be Acquired by Mallinckrodt for \$1.52/Share

Financial news for OCRX dated on 2017-08-01: Ocera Therapeutics Reports Q2 EPS \$(0.23) vs \$(0.24) Est.

Financial news for OCRX dated on 2017-06-01: Ocera Begins Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis, Results Expected By Year-End 2017

Financial news for OCRX dated on 2017-05-09: Ocera Therapeutics Reports Q1 EPS \$(0.28) vs \$(0.23) Est.

Financial news for OCRX dated on 2017-04-17: Perceptive Advisors Reports 9.11% Stake In Ocera Therapeutics

Financial news for OCRX dated on 2017-04-12: UPDATE: Ocera Says Data on OCR-002 Supports Potential for NAFLD/NASH Treatment

Financial news for OCRX dated on 2017-04-12: Ocera Therapeutics Says Will Present Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of NAFLD

Financial news for OCRX dated on 2017-03-10: Ocera Therapeutics Reports Q4 EPS (\$0.22) vs \$(0.34) Est., Sales \$512K vs \$24K in Same Qtr. Last Year

Financial news for OCRX dated on 2017-03-08: Ocera Therapeutics Shares Up 49% Following Report THat IV OCR-002 Showed Statistically Significant Reduction In Ammonia Levels Over Placebo

Financial news for OCRX dated on 2017-03-08: Ocera Therapeutics Shares to Resume Trade at 8:35 a.m. EST

Financial news for OCRX dated on 2017-03-08: Ocera Therapeutics Shares Halted News Pending

Financial news for OCRX dated on 2017-01-31: JMP Securities Downgrades Ocera Therapeutics To Market Perform

Financial news for OCRX dated on 2017-01-30: Ocera Therapeutics Shares to Resume Trade at 7:30 a.m. EST

Financial news for OCRX dated on 2017-01-30: UPDATE: Ocera Says Ammonia Scavenger OCR-002 Demonstrated Statistically Significant Reduction in Ammonia Levels OCR-002 Was Safe and Well-Tolerated

Financial news for OCRX dated on 2017-01-30: Ocera Therapeutics Reports Top-Line Results for Phase 2b Study in Hepatic Encephalopathy: Primary and Secondary Endpoints Showed Trend and Dose-Related Clinical Benefit Although Not Statistically Significant

Financial news for OCRX dated on 2017-01-30: Ocera Therapeutics Shares Halted News Pending

Financial news for OCRX dated on 2016-12-28: H.C. Wainwright Initiates Coverage On Ocera Therapeutics at Buy, Announces \$10.00 Target

Financial news for OCRX dated on 2016-11-04: Aegis Capital Initiates Coverage On Ocera Therapeutics, Inc. - Common Stock at Buy, Announces \$8.00

Financial news for OCRX dated on 2016-02-23: Brean Capital Initiates Coverage on Ocera Therapeutics at Buy, Announces \$10.00 PT, Likes Co For OCR-002 Drug Candidate

Financial news for OCRX dated on 2014-11-13: Ocera Therapeutics Reports Q3 EPS of \$(0.34) vs \$(0.50) Est; Revenue of \$233.0K vs \$200.0K Est

Financial news for OCRX dated on 2014-08-11: Ocera Therapeutics Reports Q2 EPS of \$3.24

Financial news for OCRX dated on 2014-06-11: JMP Securities Initiates Coverage on Ocera Therapeutics at Market Outperform, Announces \$15.00 PT

Financial news for OCRX dated on 2014-05-08: Ocera Therapeutics Reports Q1 EPS of \$(0.27) vs \$(0.43) Est

Financial news for OCRX dated on 2014-03-13: Ocera Therapeutics Reports Q4 EPS of \$(0.53) Which May Not Compare \$(0.21) Est

Financial news for OCRX dated on 2014-01-06: BMO Capital Upgrades Ocera Therapeutics to Outperform, Raises PT to \$26.00

Financial news for OCRX dated on 2013-12-30: Stifel Nicolaus Initiates Coverage on Ocera Therapeutics at Buy, Announces \$19.00 PT

Financial news for OCRX dated on 2013-12-17: Ocera Therapeutics And The Roche Group Enter Into Technology Transfer And License Agreement

Financial news for OCRX dated on 2013-09-03: Jeryl L Hilleman Named Ocera Therapeutics CFO